BridgeBio Pharma Inc
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM);… Read more
BridgeBio Pharma Inc (BBIO) - Net Assets
Latest net assets as of September 2025: $-1.92 Billion USD
Based on the latest financial reports, BridgeBio Pharma Inc (BBIO) has net assets worth $-1.92 Billion USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($998.25 Million) and total liabilities ($2.92 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-1.92 Billion |
| % of Total Assets | -192.61% |
| Annual Growth Rate | N/A |
| 5-Year Change | -1451.07% |
| 10-Year Change | N/A |
| Growth Volatility | 412.49 |
BridgeBio Pharma Inc - Net Assets Trend (2017–2024)
This chart illustrates how BridgeBio Pharma Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BridgeBio Pharma Inc (2017–2024)
The table below shows the annual net assets of BridgeBio Pharma Inc from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-1.46 Billion | -8.57% |
| 2023-12-31 | $-1.34 Billion | -7.84% |
| 2022-12-31 | $-1.24 Billion | -43.83% |
| 2021-12-31 | $-865.58 Million | -902.31% |
| 2020-12-31 | $107.89 Million | -77.33% |
| 2019-12-31 | $475.98 Million | +568.93% |
| 2018-12-31 | $-101.50 Million | -85.61% |
| 2017-12-31 | $-54.69 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to BridgeBio Pharma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 303483600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $196.00K | % |
| Other Comprehensive Income | $8.00K | % |
| Other Components | $1.63 Billion | % |
| Total Equity | $-1.47 Billion | 100.00% |
BridgeBio Pharma Inc Competitors by Market Cap
The table below lists competitors of BridgeBio Pharma Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ABN AMRO Bank N.V
PINK:AAVMY
|
$11.03 Billion |
|
Postal Savings Bank of China Co. Ltd
PINK:PSBKF
|
$11.06 Billion |
|
Swiss Re Ltd
PINK:SSREY
|
$11.08 Billion |
|
Gfl Environmental Holdings Inc
NYSE:GFL
|
$11.12 Billion |
|
Globe Life Inc
NYSE:GL
|
$11.03 Billion |
|
Guardant Health Inc
NASDAQ:GH
|
$11.02 Billion |
|
China Tungsten and Hightech Materials Co Ltd
SHE:000657
|
$11.02 Billion |
|
Guangdong Songfa Ceramics Co
SHG:603268
|
$11.01 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BridgeBio Pharma Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -1,354,257,000 to -1,467,904,000, a change of -113,647,000.
- Net loss of 535,762,000 reduced equity.
- Share repurchases of 7,526,000 reduced equity.
- New share issuances of 314,741,000 increased equity.
- Other comprehensive income decreased equity by 23,000.
- Other factors increased equity by 114,923,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-535.76 Million | -36.5% |
| Share Repurchases | $7.53 Million | -0.51% |
| Share Issuances | $314.74 Million | +21.44% |
| Other Comprehensive Income | $-23.00K | -0.0% |
| Other Changes | $114.92 Million | +7.83% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares BridgeBio Pharma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-0.63 | $70.94 | x |
| 2018-12-31 | $-1.78 | $70.94 | x |
| 2019-12-31 | $3.89 | $70.94 | x |
| 2020-12-31 | $0.49 | $70.94 | x |
| 2021-12-31 | $-6.03 | $70.94 | x |
| 2022-12-31 | $-8.51 | $70.94 | x |
| 2023-12-31 | $-8.32 | $70.94 | x |
| 2024-12-31 | $-7.89 | $70.94 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BridgeBio Pharma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -241.44%
- • Asset Turnover: 0.24x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-104.83%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-24.76 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-114.35 Million |
| 2019 | -63.76% | -642.10% | 0.06x | 1.55x | $-301.28 Million |
| 2020 | -774.92% | -5439.74% | 0.01x | 12.15x | $-454.51 Million |
| 2021 | 0.00% | -806.90% | 0.07x | 0.00x | $-475.50 Million |
| 2022 | 0.00% | -619.70% | 0.12x | 0.00x | $-355.72 Million |
| 2023 | 0.00% | -6913.92% | 0.02x | 0.00x | $-507.78 Million |
| 2024 | 0.00% | -241.44% | 0.24x | 0.00x | $-388.97 Million |
Industry Comparison
This section compares BridgeBio Pharma Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BridgeBio Pharma Inc (BBIO) | $-1.92 Billion | 0.00% | N/A | $11.03 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |